• About us
• Contact

Advertisement

Person › Details

Samarth (Sam) Kulkarni (CRISPR Therapeutics AG (Nasdaq: CRSP))

Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)

 

	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Product	CRISPR gene editing technology

Record changed: 2024-11-15

Advertisement

More documents for Samarth (Sam) Kulkarni

• [1] CRISPR Therapeutics AG. (11/14/24). "Press Release: CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference". Zug & Boston, MA....
• [2] CRISPR Therapeutics AG. (11/7/24). "Press Release: CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference". Zug & Boston, MA....
• [3] CRISPR Therapeutics AG. (11/5/24). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results". Zug & Boston, MA....
• [4] CRISPR Therapeutics AG. (8/5/24). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results". Zug & Boston, MA....
• [5] CRISPR Therapeutics AG. (3/13/24). "Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors". Zug & Boston, MA....
• [6] CRISPR Therapeutics AG. (2/13/24). "Press Release: CRISPR Therapeutics Announces $280 Million Registered Direct Offering". Zug & Boston, MA....
• [7] CRISPR Therapeutics AG. (2/13/24). "Press Release: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)". Z...
• [8] CRISPR Therapeutics AG. (6/13/23). "Pressemitteilung: CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference". Zug & Cambridge, MA....
• [9] CRISPR Therapeutics AG. (4/13/23). "Press Release: CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference". Zug & Cambridge, MA....
• [10] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.